Fri, Nov 21, 2014, 9:02 PM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

NanoLogix Inc. Message Board

commishfree1 12 posts  |  Last Activity: 13 hours ago Member since: Mar 15, 2014
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    BLAH BLAH BLAH!

    by heysutty Nov 20, 2014 6:32 AM
    commishfree1 commishfree1 13 hours ago Flag

    "Several companies are racing to create an easy-to-use and easy-to-transport test kit that can sniff out the disease with as little trouble as a pregnancy test. Doing so requires overcoming the big hurdles of current tests: the need to refrigerate blood and analyze results in a medical lab.
    British company Primerdesign is one of the companies taking on the challenge, and its test focuses on solving the refrigeration issues “It's all freeze-dried, so you open the packet and you see what looks like a white powder inside the tube there and you re-suspend that in some liquid," says Dr. Jim Wicks, the company's managing director. "It means that you can transport [the test kits] around Africa at room temperature - which is crucial."
    Wicks says that CDC is already using some of his kits in West Africa, and that Primerdesign has 50,000 kits ready to ship.
    French pharmaceutical firm Vedalab is tackling the problem from the other side. Its test, called eZYSCREEN, is similar to a home pregnancy test: If there's a positive result, a small stripe appears in a window on the hand-held device. That means the test wouldn't have to be processed in a lab.
    There are still other companies in the running as well. Colorado's Corgenix Medical Corp. is working on a test kit, and the FDA has reportedly approached Pennsylvania-based company OraSure to develop one as well. OraSure already produces OraQuick, which tests for HIV with a saliva swab. There's hope the company could develop a similar test for Ebola that wouldn't require drawing blood."

  • Reply to

    BLAH BLAH BLAH!

    by heysutty Nov 20, 2014 6:32 AM
    commishfree1 commishfree1 13 hours ago Flag

    FDA Director Margaret Hamburg 10/28/2014 - "In addition, under the FDA’s Emergency Use Authorization (EUA) authority, we can allow the use of an unapproved medical product—or an unapproved use of an approved medical product—for a larger population during emergencies, when, among other reasons, based on scientific evidence available, there is no adequate, approved, and available alternative. To date, FDA has authorized the use of five diagnostic tests during this Ebola epidemic: one was developed by DoD, two were developed by CDC, and this week FDA issued EUAs for two new, quicker Ebola tests made by BioFire Defense.
    To further augment diagnostic capacity, we have contacted several commercial developers that we know are capable of developing rapid diagnostic tests and have encouraged them to work with us to quickly develop and make available such tests. Several entities have expressed interest and have initiated discussions with FDA."

    Hopefully, they have initiated discussions with the FDA.

  • Reply to

    BLAH BLAH BLAH!

    by heysutty Nov 20, 2014 6:32 AM
    commishfree1 commishfree1 Nov 20, 2014 10:42 AM Flag

    "Based on the findings of this study, Cynapsus is planning to conduct pivotal studies of longer duration and with larger patient numbers to confirm these results. These pivotal studies are expected to form the registration package necessary for a 505(b)(2) New Drug Application with the U.S. Food and Drug Administration expected to be submitted in 2016. "

    You're probably right, next time this year they may have the PIII results released....that is the time when things typically get heated up with these types of drug development stocks.

  • Reply to

    BLAH BLAH BLAH!

    by heysutty Nov 20, 2014 6:32 AM
    commishfree1 commishfree1 Nov 20, 2014 10:27 AM Flag

    Good job on a Parkinson's drug candidate....did you buy shares at .50 or $1.25?
    Genalyte isn't publicly traded. But getting back to the "mouse trap" part of it...considering your emotional attachment to NNLX (basically you married it) I doubt you would know what a better "mouse trap" looks like even if it jumped up and bit you in the........never mind.

  • Reply to

    BLAH BLAH BLAH!

    by heysutty Nov 20, 2014 6:32 AM
    commishfree1 commishfree1 Nov 20, 2014 9:36 AM Flag

    "The Genalyte test, which is performed on the company's commercially available platform, is processed with a single drop of blood from a finger #$%$ and offers results in as little as 10 minutes. Genalyte's silicon chip technology offers a new platform for testing that fills a key gap in the diagnostics market—offering the high accuracy and sensitivity of gold standard testing mechanisms, with the diagnostic speed, high volume testing capacity, and low cost of other rapid tests. Additionally, Genalyte's technology, which can process as many as 100 tests per hour, can be deployed to hospitals and airports as well as to the front lines in West Africa, where many victims are currently not being tested.
    "Working together with the FDA, CDC, policymakers and health organizations we are committed to expediting the necessary protocols and distributing our tests to all those in need," said Genalyte Founder and CEO Cary Gunn. "With FDA authorization, our Genalyte team can deploy tests immediately to help detect the virus sooner, stop the spread of the disease, and facilitate more timely treatment of those infected."

    This sound like a better "mouse trap" coming along, Erick?

  • commishfree1 commishfree1 Nov 19, 2014 6:08 PM Flag

    Change the capture antibody, change the microplate washing steps?

  • Reply to

    Not one share traded

    by rayludwiczak Nov 14, 2014 4:48 PM
    commishfree1 commishfree1 Nov 15, 2014 10:32 AM Flag

    A close 2nd would be CEMI....had a 2.1 million share day at the end of Oct.....but only a 1900 share day at the end of Sept. Have to admire the tenacity of those "Ebola" day-traders. They came and left like a swarm of locusts.

  • Reply to

    Ebola

    by nanofanboyyeahbaby Nov 11, 2014 1:14 PM
    commishfree1 commishfree1 Nov 13, 2014 7:05 AM Flag

    Nov. 13, 2014 /PRNewswire/ --" Cepheid (CPHD) today announced that it has been awarded a grant of up to $3.3 million co-financed by the Paul G. Allen Family Foundation and the Bill & Melinda Gates Foundation to develop Xpert® Ebola, a rapid test that could be run on Cepheid's installed base of more than 3,500 GeneXpert® Systems in developing countries, including more than 1,000 in Africa. The test is expected to be offered on an emergency use only basis.
    "While we are all hopeful that the Ebola epidemic dissipates quickly, we welcome the opportunity to develop an accurate, rapid and easy-to-use test with the potential to strengthen the arsenal of tools being deployed to address the current situation," said John Bishop, Cepheid's Chairman and CEO. "Cepheid has historically played a leading role in developing molecular diagnostics as an aid to infection control efforts, and the current Ebola crisis represents an extreme example of the need for sensitive, rapid, and easy to use diagnostics to inform patient management and isolation requirements."
    "Cepheid is well positioned to respond quickly to this urgent imperative. We are leveraging our significant investments in development of ultrasensitive HIV and TB detection technologies, and are borrowing on previous experience with an Ebola project to expedite delivery of the initial prototype and emergency use only product," said David Persing, MD, PhD, Cepheid's Chief Medical and Technology Officer. "We expect this technology to facilitate high throughput testing requirements of Ebola Treatment Units, as well as deployment of mobile laboratories for field surveillance."

    Pretty amazing how fast a grant or partnership can be consummated.

  • Reply to

    "60 Minutes" segment on Elbola

    by james997 Nov 10, 2014 4:19 PM
    commishfree1 commishfree1 Nov 12, 2014 9:19 AM Flag

    11/2/2014--"Lucigen Corp. is asking the U.S. Food and Drug Administration for emergency-use authorization to get the test on the market rapidly, saying it is believed to be the only test of its kind.
    Derived from enzymes discovered in the hot springs of Yellowstone National Park more than a decade ago, the test already is being tried in parts of West Africa where Ebola has spread. A U.S. government agency is evaluating its performance against other tests, said Hemanth Shenoi, Lucigen’s director of business development. He declined to say which agency.
    “In cases like Ebola, time is of the essence,” Shenoi said. He said Lucigen has been in discussions with the FDA over the past week but does not know how soon a decision may come.
    The Middleton company has plenty of company in the rush to find solutions to the Ebola outbreak. Just last week, the FDA fast-tracked two new tests by BioFire, a Salt Lake City diagnostics subsidiary of a French firm.
    “There are, obviously, many companies that are pursuing rapid diagnostics to help address the threat,” said Jeffrey Elliott, life sciences and diagnostics analyst at Robert W. Baird & Co. in Chicago. "

    The Africa market needs the help.....this analyst says it's a crowded field.

  • Reply to

    Another week gone by

    by omarhatesyou Nov 8, 2014 4:57 AM
    commishfree1 commishfree1 Nov 8, 2014 8:43 AM Flag

    OK, so I looked it up and this appears to be the crux of the matter. Lucigen obtains a $1.7 million grant from the NIAID...and Corgenix obtained a $2.9 million grant from the NIH. A fair question to Barnhizer is what success has he had in obtaining such a grant? Without federal assistance, what is NNLX's cash balance position in order to perform necessary testing at a BSL-4 facility? Or is this where the corporate partner comes in... with the money?

  • Reply to

    Another week gone by

    by omarhatesyou Nov 8, 2014 4:57 AM
    commishfree1 commishfree1 Nov 8, 2014 8:04 AM Flag

    Chander (senior Lucigen scientist) stressed that the company does not use hemorrhagic fever viruses at its labs in central Wisconsin. Instead, they have an ongoing collaboration with Thomas Geisbert and the Biosafety Level 4 facilities of Galveston National Labs, which is part of the University of Texas Medical Branch. "We don't even go near the VHF agents," Chander said. "We do our work here and then send it to them, and when the time comes, they [run the assay] with the real viruses."

    Sounds like the key is a collaboration with a BSL-4 facility.

  • Reply to

    Another week gone by

    by omarhatesyou Nov 8, 2014 4:57 AM
    commishfree1 commishfree1 Nov 8, 2014 7:45 AM Flag

    11/3/2014-- "But a couple of months ago, the Centers for Disease Control and Prevention contacted Lucigen about the rapid, on-the-spot pathogen detection technology that the 52-person company has been developing in Middleton, WI. Lucigen, founded in 1998 as a supplier of life sciences research products, had in 2012 won a three-year, $1.7 million grant from the National Institute of Allergy and Infectious Diseases to help further development of the diagnostic technology.
    The idea is a nucleic-acid-based test for quickly spotting infections in patients’ samples right at the point of care in, say, a hospital or doctor’s office. The technology has a multitude of applications, Lucigen says, from sniffing out common infections like flu and strep to diagnosing more serious diseases—including Ebola.
    Lucigen’s technology drew the CDC’s attention because the diagnostic test can be performed by healthcare workers in the field, and it returns results within 30 minutes or so. That would be a huge improvement over the current practice of shipping samples to a far-away lab for testing by highly trained technicians, a process that typically doesn’t return results for a couple of days.
    Lucigen intended for its diagnostic platform’s first commercial use to be in detecting Clostridium difficile, or C. diff, a bacterial infection that can cause diarrhea and life-threatening inflammation of the colon. The company is still planning to start a clinical trial testing for C. diff early next year, and if it receives U.S. Food & Drug Administration approval, Lucigen could begin selling the product in 2016, business development director Hemanth Shenoi said."

    Maybe their talk with BARDA turns into something....but it looks like the CDC sought these guys out.

NNLX
0.06-0.01(-12.15%)Nov 21 3:51 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Foot Locker, Inc.
NYSEFri, Nov 21, 2014 4:00 PM EST
GameStop Corp.
NYSEFri, Nov 21, 2014 4:04 PM EST
Aruba Networks, Inc.
NasdaqGSFri, Nov 21, 2014 4:00 PM EST